Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;9(5):e681-e690.
doi: 10.1016/S2214-109X(20)30539-8.

Urgently seeking efficiency and sustainability of clinical trials in global health

Jay J H Park  1 , Rebecca F Grais  2 , Monica Taljaard  3 , Etheldreda Nakimuli-Mpungu  4 , Fyezah Jehan  5 , Jean B Nachega  6 , Nathan Ford  7 , Denis Xavier  8 , Andre P Kengne  9 , Per Ashorn  10 , Maria Eugenia Socias  11 , Zulfiqar A Bhutta  12 , Edward J Mills  13
Affiliations
Review

Urgently seeking efficiency and sustainability of clinical trials in global health

Jay J H Park et al. Lancet Glob Health. 2021 May.

Abstract

This paper shows the scale of global health research and the context in which we frame the subsequent papers in the Series. In this Series paper, we provide a historical perspective on clinical trial research by revisiting the 1948 streptomycin trial for pulmonary tuberculosis, which was the first documented randomised clinical trial in the English language, and we discuss its close connection with global health. We describe the current state of clinical trial research globally by providing an overview of clinical trials that have been registered in the WHO International Clinical Trial Registry since 2010. We discuss challenges with current trial planning and designs that are often used in clinical trial research undertaken in low-income and middle-income countries, as an overview of the global health trials landscape. Finally, we discuss the importance of collaborative work in global health research towards generating sustainable and culturally appropriate research environments.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

DX reports grants from AstraZeneca, grants from Boehringer Ingelheim, grants from Bristol Myers Squibb, grants from Coca-Cola India, speaker’s fees from Eli Lilly, speaker’s fees from the Indian Council of Medical Research, grants from Pfizer, speaker’s fees from Sanofi, grants from the Medical Research Council, UK, and grants from the Wellcome Trust, outside of the submitted work. All other authors declare no competing interests.

Figures

Figure 1:
Figure 1:. Global overview of clinical trial research
(A) Percentage of registered randomised clinical trials worldwide. (B) Percentage of trials that are cluster-randomised, by country, from the WHO International Clinical Trials Registry Platform from Jan 1, 2010, to Nov 5, 2019. (C) Number of master protocols registered or undertaken worldwide as of Dec 11, 2019.
Figure 2:
Figure 2:. Conventional fixed trial designs and common adaptive trial designs
(A) A two-arm randomised clinical trial with conventional fixed trial design. (B) A two-arm trial with SSR. If the first interim analysis shows worse results than expected, an SSR can be carried out by use of the interim results. An SSR is not permitted in a traditional non-adaptive trial, so even when the original planned sample size is reached, the trial might be underpowered. If SSR is permitted, the sample size could be increased to ensure that the trial is adequately powered. (C) A two-arm trial with response adaptive randomisation. The response adaptive randomisation design allows for preferential assignment of interventions that show favourable interim results. In this example, the response adaptive randomisation design allows for an increased allocation ratio to treatment 1 based on the interim results. SSR=sample size reassessment.
See this image and copyright information in PMC

Comment in

  • Challenges of adopting new trial designs in LMICs.
    Bhandari N, Upadhyay RP, Chowdhury R, Taneja S. Bhandari N, et al. Lancet Glob Health. 2021 May;9(5):e575-e576. doi: 10.1016/S2214-109X(21)00168-6. Lancet Glob Health. 2021. PMID: 33865466 No abstract available.

References

    1. Koplan JP, Bond TC, Merson MH, et al.Towards a common definition of global health. Lancet 2009; 373: 1993–95. - PMC - PubMed
    1. Fried LP, Bentley ME, Buekens P, et al.Global health is public health. Lancet 2010; 375: 535–37. - PubMed
    1. Vos T, Abajobir AA, Abate KH, et al.Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–59. - PMC - PubMed
    1. Kyu HH, Abate D, Abate KH, et al.Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1859–922. - PMC - PubMed
    1. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1084–150. - PMC - PubMed

Publication types

MeSH terms